Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) EBIT (2016 - 2025)

Historic EBIT for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to -$1.2 million.

  • Arcadia Biosciences' EBIT rose 3454.55% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year decrease of 3283.87%. This contributed to the annual value of -$3.6 million for FY2024, which is 4021.63% up from last year.
  • According to the latest figures from Q3 2025, Arcadia Biosciences' EBIT is -$1.2 million, which was up 3454.55% from -$501000.0 recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' EBIT ranged from a high of $2.0 million in Q2 2024 and a low of -$13.8 million during Q4 2021
  • For the 5-year period, Arcadia Biosciences' EBIT averaged around -$3.4 million, with its median value being -$2.3 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 28481.72% in 2021, then skyrocketed by 23617.61% in 2024.
  • Quarter analysis of 5 years shows Arcadia Biosciences' EBIT stood at -$13.8 million in 2021, then surged by 66.26% to -$4.7 million in 2022, then surged by 74.39% to -$1.2 million in 2023, then tumbled by 91.03% to -$2.3 million in 2024, then skyrocketed by 49.45% to -$1.2 million in 2025.
  • Its EBIT stands at -$1.2 million for Q3 2025, versus -$501000.0 for Q2 2025 and $530000.0 for Q1 2025.